{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:19:49Z","timestamp":1787062789417,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12325-022-02092-7","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:12:31Z","timestamp":1647216751000},"page":"1895-1914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8918-7075","authenticated-orcid":false,"given":"Dave","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipong","family":"Maneechotesuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-5621","authenticated-orcid":false,"given":"Peter","family":"Daley-Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-3251","authenticated-orcid":false,"given":"Elvis","family":"Irusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-9319","authenticated-orcid":false,"given":"Bhumika","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boucot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Berend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2092_CR1","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf. Accessed 30 Nov 2021."},{"key":"2092_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/PPA.S234651","volume":"14","author":"S Amin","year":"2020","unstructured":"Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Understanding patient perspectives on medication adherence in asthma: a targeted review of qualitative studies. Patient Prefer Adherence. 2020;14:541\u201351.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"2092_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2011.09.011","volume":"128","author":"LK Williams","year":"2011","unstructured":"Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185-1191 e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2092_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1183\/09031936.00075614","volume":"45","author":"M Engelkes","year":"2015","unstructured":"Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396\u2013407.","journal-title":"Eur Respir J"},{"issue":"4 Pt 2","key":"2092_CR5","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/S0091-6749(98)70004-1","volume":"102","author":"HW Kelly","year":"1998","unstructured":"Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic\/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102(4 Pt 2):S36\u201351.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2092_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcp.12637","volume":"80","author":"PT Daley-Yates","year":"2015","unstructured":"Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372\u201380.","journal-title":"Br J Clin Pharmacol"},{"key":"2092_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01976-4","author":"P Daley-Yates","year":"2021","unstructured":"Daley-Yates P, Aggarwal B, Lulic Z, et al. Pharmacology versus convenience: a benefit\/risk analysis of regular maintenance versus infrequent or as-needed inhaled corticosteroid use in mild asthma. Adv Ther. 2021. https:\/\/doi.org\/10.1007\/s12325-021-01976-4.","journal-title":"Adv Ther"},{"issue":"20","key":"2092_CR8","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","volume":"378","author":"ED Bateman","year":"2018","unstructured":"Bateman ED, Reddel HK, O\u2019Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877\u201387.","journal-title":"N Engl J Med"},{"issue":"21","key":"2092_CR9","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020\u201330.","journal-title":"N Engl J Med"},{"issue":"10202","key":"2092_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","volume":"394","author":"J Hardy","year":"2019","unstructured":"Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919\u201328.","journal-title":"Lancet"},{"issue":"20","key":"2092_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","volume":"378","author":"PM O'Byrne","year":"2018","unstructured":"O\u2019Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865\u201376.","journal-title":"N Engl J Med"},{"issue":"2","key":"2092_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bcp.14406","volume":"87","author":"P Daley-Yates","year":"2021","unstructured":"Daley-Yates P, Brealey N, Thomas S, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87(2):483\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"2092_CR13","unstructured":"GlaxoSmithKline plc. Fluticasone propionate Summary of Product Characteristics. Series Fluticasone propionate Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/846\/smpc#gref. Accessed 30 Nov 2021."},{"key":"2092_CR14","unstructured":"Orion Pharma (UK) Limited. Budesonide Summary of Product Characteristics. Series Budesonide Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/242\/smpc#gref. Accessed 30 Nov 2021."},{"key":"2092_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JAA.S4214","volume":"2","author":"KR Murphy","year":"2009","unstructured":"Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63\u201372.","journal-title":"J Asthma Allergy"},{"issue":"3","key":"2092_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4187\/respcare.03200","volume":"60","author":"CB B\u00e5rnes","year":"2015","unstructured":"B\u00e5rnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455\u201368.","journal-title":"Respir Care"},{"issue":"5","key":"2092_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/thx.53.5.419","volume":"53","author":"J Lotvall","year":"1998","unstructured":"Lotvall J, Inman M, O\u2019Byrne P. Measurement of airway hyperresponsiveness: new considerations. Thorax. 1998;53(5):419\u201324.","journal-title":"Thorax"},{"issue":"10","key":"2092_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/thorax.57.10.865","volume":"57","author":"GP Currie","year":"2002","unstructured":"Currie GP, Fowler SJ, Wilson AM, et al. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax. 2002;57(10):865\u20138.","journal-title":"Thorax"},{"issue":"8","key":"2092_CR19","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0149-2918(03)80212-6","volume":"25","author":"P Kuna","year":"2003","unstructured":"Kuna P, Joubert JR, Greefhorst LA, Magnussen H. A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Clin Ther. 2003;25(8):2182\u201397.","journal-title":"Clin Ther"},{"issue":"3","key":"2092_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1752-699X.2009.00134.x","volume":"3","author":"J Wickstrom","year":"2009","unstructured":"Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide\/formoterol for maintenance and reliever asthma therapy in Denmark\u2013cost-effectiveness analysis based on five randomised controlled trials. Clin Respir J. 2009;3(3):169\u201380.","journal-title":"Clin Respir J"},{"issue":"5","key":"2092_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1183\/09031936.05.00028305","volume":"26","author":"C Vogelmeier","year":"2005","unstructured":"Vogelmeier C, D\u2019Urzo A, Pauwels R, et al. Budesonide\/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J. 2005;26(5):819\u201328.","journal-title":"Eur Respir J"},{"issue":"7","key":"2092_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/rmed.2000.0796","volume":"94","author":"H Tukiainen","year":"2000","unstructured":"Tukiainen H, Taivainen A, Majander R, et al. Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma. Respir Med. 2000;94(7):678\u201383.","journal-title":"Respir Med"},{"issue":"6","key":"2092_CR23","first-page":"255","volume":"12","author":"M Trautmann","year":"2007","unstructured":"Trautmann M, Banik N, Tews JT, Jorres RA, Nowak D. Efficacy of the combination of fluticasone propionate and salmeterol in patients with moderate persistent asthma within a \u201creal-life\u201d setting. Eur J Med Res. 2007;12(6):255\u201363.","journal-title":"Eur J Med Res"},{"issue":"19","key":"2092_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1056\/NEJMoa1511049","volume":"374","author":"DA Stempel","year":"2016","unstructured":"Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"2092_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5414\/CP202224","volume":"53","author":"B St\u00e4llberg","year":"2015","unstructured":"St\u00e4llberg B, Naya I, Ekelund J, Eckerwall G. Real-life use of budesonide\/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther. 2015;53(6):447\u201355.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2 Pt 1","key":"2092_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1164\/ajrccm.161.2.9905091","volume":"161","author":"G Shapiro","year":"2000","unstructured":"Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000;161(2 Pt 1):527\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2092_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.rmed.2009.10.025","volume":"104","author":"PM Renzi","year":"2010","unstructured":"Renzi PM, Howard LA, Ortega HG, Ahmad FF, Chapman KR. Low-dose fluticasone propionate with and without salmeterol in steroid-naive patients with mild, uncontrolled asthma. Respir Med. 2010;104(4):510\u20137.","journal-title":"Respir Med"},{"issue":"2","key":"2092_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1378\/chest.129.2.246","volume":"129","author":"KF Rabe","year":"2006","unstructured":"Rabe KF, Pizzichini E, St\u00e4llberg B, et al. Budesonide\/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129(2):246\u201356.","journal-title":"Chest"},{"issue":"5","key":"2092_CR29","doi-asserted-by":"publisher","first-page":"1083-9","DOI":"10.1016\/j.jaci.2009.02.034","volume":"123","author":"ID Pavord","year":"2009","unstructured":"Pavord ID, Jeffery PK, Qiu Y, et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide\/formoterol. J Allergy Clin Immunol. 2009;123(5):1083-9-1089 e1-7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2092_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2213-2600(13)70007-9","volume":"1","author":"M Patel","year":"2013","unstructured":"Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013;1(1):32\u201342.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2092_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.rmed.2005.09.006","volume":"100","author":"B Lundback","year":"2006","unstructured":"Lundback B, Ronmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med. 2006;100(1):2\u201310.","journal-title":"Respir Med"},{"issue":"3","key":"2092_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.rmed.2008.10.015","volume":"103","author":"B Lundback","year":"2009","unstructured":"Lundback B, Ronmark E, Lindberg A, et al. Asthma control over 3 years in a real-life study. Respir Med. 2009;103(3):348\u201355.","journal-title":"Respir Med"},{"key":"2092_CR33","doi-asserted-by":"publisher","first-page":"g3009","DOI":"10.1136\/bmj.g3009","volume":"348","author":"RJ Loymans","year":"2014","unstructured":"Loymans RJ, Gemperli A, Cohen J, et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ. 2014;348:g3009.","journal-title":"BMJ"},{"issue":"17","key":"2092_CR34","first-page":"2994","volume":"125","author":"JT Lin","year":"2012","unstructured":"Lin JT, Chen P, Zhou X, et al. Budesonide\/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chin Med J (Engl). 2012;125(17):2994\u20133001.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2092_CR35","doi-asserted-by":"publisher","first-page":"00701-2020","DOI":"10.1183\/23120541.00701-2020","volume":"7","author":"L Hatter","year":"2021","unstructured":"Hatter L, Bruce P, Braithwaite I, et al. ICS-formoterol reliever versus ICS and short-acting beta2-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res. 2021;7(1):00701\u20132020.","journal-title":"ERJ Open Res"},{"issue":"7","key":"2092_CR36","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.clinthera.2007.07.021","volume":"29","author":"RL Cowie","year":"2007","unstructured":"Cowie RL, Boulet LP, Keith PK, et al. Tolerability of a salmeterol xinafoate\/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Clin Ther. 2007;29(7):1390\u2013402.","journal-title":"Clin Ther"},{"key":"2092_CR37","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.2147\/DDDT.S266177","volume":"14","author":"SL Cheng","year":"2020","unstructured":"Cheng SL, Ho ML, Lai YF, et al. Budesonide\/formoterol anti-inflammatory reliever and maintenance or fluticasone propionate\/salmeterol plus as-needed, short-acting beta2 agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study. Drug Des Devel Ther. 2020;14:5441\u201350.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"2092_CR38","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.rmed.2010.04.001","volume":"104","author":"P Chanez","year":"2010","unstructured":"Chanez P, Stallaert R, Reznikova E, et al. Effect of salmeterol\/fluticasone propionate combination on airway hyper-responsiveness in patients with well-controlled asthma. Respir Med. 2010;104(8):1101\u20139.","journal-title":"Respir Med"},{"key":"2092_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007313.pub3","author":"CJ Cates","year":"2013","unstructured":"Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD007313.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2092_CR40","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.rmed.2007.07.014","volume":"101","author":"J Bousquet","year":"2007","unstructured":"Bousquet J, Boulet LP, Peters MJ, et al. Budesonide\/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol\/fluticasone. Respir Med. 2007;101(12):2437\u201346.","journal-title":"Respir Med"},{"issue":"3","key":"2092_CR41","doi-asserted-by":"publisher","first-page":"600-8","DOI":"10.1016\/j.jaci.2009.11.033","volume":"125","author":"ED Bateman","year":"2010","unstructured":"Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010;125(3):600-8-608 e1-608 e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2092_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","volume":"170","author":"ED Bateman","year":"2004","unstructured":"Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836\u201344.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2092_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1742-1241.2007.01338.x","volume":"61","author":"P Kuna","year":"2007","unstructured":"Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide\/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61(5):725\u201336.","journal-title":"Int J Clin Pract"},{"issue":"14","key":"2092_CR44","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jama.2018.2769","volume":"319","author":"DM Sobieraj","year":"2018","unstructured":"Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. J Am Med Assoc. 2018;319(14):1485\u201396.","journal-title":"J Am Med Assoc"},{"issue":"6","key":"2092_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/02770900701421930","volume":"44","author":"RA Rojas","year":"2007","unstructured":"Rojas RA, Paluga I, Goldfrad CH, Duggan MT, Barnes N. Initiation of maintenance therapy with salmeterol\/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. J Asthma. 2007;44(6):437\u201341.","journal-title":"J Asthma"},{"issue":"6","key":"2092_CR46","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1164\/ajrccm.162.6.9912072","volume":"162","author":"LP Nielsen","year":"2000","unstructured":"Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000;162(6):2053\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2092_CR47","first-page":"16","volume":"59","author":"M Masoli","year":"2004","unstructured":"Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004;59(1):16\u201320.","journal-title":"Thorax"},{"issue":"4","key":"2092_CR48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1183\/09031936.04.00076604","volume":"23","author":"M Masoli","year":"2004","unstructured":"Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004;23(4):552\u20138.","journal-title":"Eur Respir J"},{"issue":"2","key":"2092_CR49","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/resp.12425","volume":"20","author":"CH Lin","year":"2015","unstructured":"Lin CH, Hsu JY, Hsiao YH, et al. Budesonide\/formoterol maintenance and reliever therapy in asthma control: acute, dose-related effects and real-life effectiveness. Respirology. 2015;20(2):264\u201372.","journal-title":"Respirology"},{"issue":"10","key":"2092_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/thorax.57.10.889","volume":"57","author":"SA Kharitonov","year":"2002","unstructured":"Kharitonov SA, Donnelly LE, Montuschi P, et al. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax. 2002;57(10):889\u201396.","journal-title":"Thorax"},{"issue":"3","key":"2092_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2332\/allergolint.08-OA-0065","volume":"58","author":"M Hoshino","year":"2009","unstructured":"Hoshino M, Handa H, Miyazawa T. Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. Allergol Int. 2009;58(3):357\u201363.","journal-title":"Allergol Int"},{"issue":"5","key":"2092_CR52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1742-1241.2009.02320.x","volume":"64","author":"SJ Edwards","year":"2010","unstructured":"Edwards SJ, von Maltzahn R, Naya IP, Harrison T. Budesonide\/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int J Clin Pract. 2010;64(5):619\u201327.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"2092_CR53","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1365-2222.2011.03928.x","volume":"42","author":"K Czarnecka","year":"2012","unstructured":"Czarnecka K, Chapman KR. The clinical impact of single inhaler therapy in asthma. Clin Exp Allergy. 2012;42(7):1006\u201313.","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"2092_CR54","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1034\/j.1398-9995.2003.00188.x","volume":"58","author":"GP Currie","year":"2003","unstructured":"Currie GP, Syme-Grant NJ, McFarlane LC, Carey FA, Lipworth BJ. Effects of low dose fluticasone\/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy. 2003;58(7):602\u20137.","journal-title":"Allergy"},{"issue":"8","key":"2092_CR55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/thx.2009.128504","volume":"65","author":"KR Chapman","year":"2010","unstructured":"Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010;65(8):747\u201352.","journal-title":"Thorax"},{"issue":"1","key":"2092_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0149-2918(02)85002-0","volume":"24","author":"J Bousquet","year":"2002","unstructured":"Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002;24(1):1\u201320.","journal-title":"Clin Ther"},{"issue":"1","key":"2092_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaci.2013.10.053","volume":"133","author":"R Beasley","year":"2014","unstructured":"Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid\/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol. 2014;133(1):39\u201341.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2092_CR58","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jaci.2006.07.002","volume":"118","author":"BG Bender","year":"2006","unstructured":"Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate\/salmeterol combination therapy. J Allergy Clin Immunol. 2006;118(4):899\u2013904.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2092_CR59","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jaci.2014.05.041","volume":"134","author":"JM Foster","year":"2014","unstructured":"Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin Immunol. 2014;134(6):1260-1268 e3.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2092_CR60","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","volume":"107","author":"MJ Makela","year":"2013","unstructured":"Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481\u201390.","journal-title":"Respir Med"},{"key":"2092_CR61","doi-asserted-by":"publisher","first-page":"16038","DOI":"10.1038\/npjpcrm.2016.38","volume":"26","author":"RL DiSantostefano","year":"2016","unstructured":"DiSantostefano RL, Boudiaf N, Stempel DA, Barnes NC, Greening AP. The frequency of, and adherence to, single maintenance and reliever therapy instructions in asthma: a descriptive analysis. NPJ Prim Care Respir Med. 2016;26:16038.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"6","key":"2092_CR62","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.rmed.2010.11.021","volume":"105","author":"AC Boyter","year":"2011","unstructured":"Boyter AC, Ford NH, Zlotos L. Audit of budesonide\/formoterol prescribing for asthma in community pharmacy in the U.K. Respir Med. 2011;105(6):864\u20138.","journal-title":"Respir Med"},{"issue":"2","key":"2092_CR63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/thorax.2003.011858","volume":"59","author":"PG Gibson","year":"2004","unstructured":"Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax. 2004;59(2):94\u20139.","journal-title":"Thorax"},{"issue":"4","key":"2092_CR64","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1378\/chest.118.4.1049","volume":"118","author":"I Aziz","year":"2000","unstructured":"Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest. 2000;118(4):1049\u201358.","journal-title":"Chest"},{"issue":"4","key":"2092_CR65","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/thorax.57.4.309","volume":"57","author":"C Ward","year":"2002","unstructured":"Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002;57(4):309\u201316.","journal-title":"Thorax"}],"updated-by":[{"DOI":"10.1007\/s12325-022-02209-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02092-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T06:24:17Z","timestamp":1655533457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02092-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02092-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-022-02209-y","URL":"https:\/\/doi.org\/10.1007\/s12325-022-02209-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}